scholarly journals Estradiol Effects on the Growth Hormone/Insulin-Like Growth Factor-1 Axis in Amenorrheic Athletes

2003 ◽  
Vol 28 (1) ◽  
pp. 64-78 ◽  
Author(s):  
Debra L. Waters ◽  
Richard I. Dorin ◽  
Clifford R. Qualls ◽  
Brent C. Ruby ◽  
Richard N. Baumgartner ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Growth Hormone ◽  
Growth Factor ◽  
Free Fatty Acids ◽  
Binding Protein ◽  
Nutritional Deficiencies ◽  
Insulin Like Growth Factor ◽  
Factor Binding ◽  
Transdermal Estradiol ◽  
Igfbp 3

Disruption of the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis has been reported and studied in menopause, hypothalamic amenorrhea, and anorexia nervosa, but not in weight-stable amenorrheic athletes. We investigated the effects of short-term transdermal estradiol on basal and exercise-stimulated serum GH, IGF-1, and associated binding proteins (IGFBP-1 and IGFBP-3) in seven weight-stable female amenorrheic athletes with percentage body fats greater that 12%. Each subject received a 72 h placebo patch followed by 144 h of transdermal estradiol. Serum samples for GH, IGF-1, IGFBP-1, and IGFBP-3 were obtained at baseline (t1), 72 hr (t2), 144 hr (t3), and during three 90-minute trials of aerobic exercise. Basal, and exercise GH, IGF-1, and IGFBP-1 were not different between trials. Baseline IGFBP-3 decreased from t1 to t2 (p = 0.04) and serum free fatty acids increased from t1 to t2, and t1 to t3 (p = 0.04, and 0.02 respectively). These findings differ from postmenopausal women, and women having weightloss-associated amenorrhea, suggesting that estrogen, exercise, and nutritional deficiencies may have independent effects on the GH/IGF-1 axis. Key words: transdermal estradiol, insulin-like growth factor binding protein-3, insulin-like growth factor binding protein-1, free fatty acids

Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity

1993 ◽  
Vol 128 (2) ◽  
pp. 144-149 ◽  
Author(s):  
Hannah Kanety ◽  
Avraham Karasik ◽  
Beatrice Klinger ◽  
Aviva Silbergeld ◽  
Zvi Laron
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Binding Protein ◽  
Serum Insulin ◽  
Continuous Treatment ◽  
Insulin Like Growth Factor ◽  
Factor Binding ◽  
Long Term Treatment ◽  
Igf I ◽  
Igfbp 3

Insulin-like growth factor binding protein-3 (IGFBP-3) is the major carrier of insulin-like growth factor I (IGF-1) in serum, and its production is growth hormone (GH) dependent. It is unclear whether in humans IGFBP-3 production is directly regulated by GH or mediated via IGF-I. We addressed this question in six patients with Laron-type dwarfism, a syndrome characterized by the absence of GH receptor activity (LTD), who were chronically treated with recombinant IGF-I. Analysis of the electrophoretic profiles of serum IGFBPs in these patients by Western ligand blotting revealed an extremely low IGFBP-3 level. A striking progressive increase in serum IGFBP-3 was observed with continuous treatment, despite the absence of GH action. In LTD children, serum IGFBP-3 increased up to 19-fold after six months of therapy and equalled levels observed in controls, whereas in adult LTD patients the increase was smaller. A rise in serum levels of 34, 30 and 24 kDa BPs (presumably IGFBP-2, -1 and -4, respectively was also noted with chronic IGF-I therapy. This proof of GH-independent induction of IGFBP-3 by IGF-1 may be a major advantage in the therapeutic use of biosynthetic IGF-I in several types of short stature children.

Efficacy of insulin-like growth factor binding protein 3 in predicting the growth hormone response to provocative testing in children treated with cranial irradiation

1993 ◽  
Vol 129 (6) ◽  
pp. 511-515 ◽  
Author(s):  
Charles Sklar ◽  
Kyriakie Sarafoglou ◽  
Elizabeth Whittam
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Screening Test ◽  
Gh Deficiency ◽  
Binding Protein ◽  
Bone Age ◽  
Cranial Irradiation ◽  
Insulin Like Growth Factor ◽  
Factor Binding ◽  
Igfbp 3

Recent data suggest that the plasma concentration of insulin-like growth factor binding protein 3 (IGFBP-3) is useful as a screening test for growth hormone (GH) deficiency. In this study, we measured by radioimmunoassay the levels of IGFBP-3 in a group of 20 subjects (12 males) of 5 years and 7 months to 16 years of age undergoing standard GH testing following cranial irradiation. The patients had received 1800 to > 6000 cGy of radiation to the hypothalamic-pituitary region, a median of 2.7 years (range 2–7 years) prior to testing. The IGFBP-3 concentrations were discordant with the results of GH testing 60% (12/20) of the time. Although IGFBP-3 levels were below the mean for age in 14 of 15 GH-deficient (peak GH <10 μg/l) patients, only three of 15 GH-deficient patients had IGFBP-3 concentrations that fell below age-adjusted norms. In contrast, the IGFBP-3 levels were within the normal range in all five patients with normal GH responses. The low sensitivity (20%) of IGFBP-3 in predicting the subjects with abnormal responses was not improved by adjusting the values for bone age or stage of puberty. We conclude that a single plasma determination of IGFBP-3 is not a useful screening test for GH deficiency among patients previously treated with cranial irradiation.

scholarly journals Usefulness and Limitation of Measurement of Insulin-Like Growth Factor Binding Protein-3(IGFBP-3) for Diagnosis of Growth Hormone Deficiency.

1992 ◽  
Vol 39 (6) ◽  
pp. 585-591 ◽  
Author(s):  
YUKIHIRO HASEGAWA ◽  
TOMONOBU HASEGAWA ◽  
TAIJI ASO ◽  
SHINOBU KOTOH ◽  
YUTAKA TSUCHIYA ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Growth Hormone Deficiency ◽  
Binding Protein ◽  
Hormone Deficiency ◽  
Insulin Like Growth Factor ◽  
Factor Binding ◽  
Igfbp 3
Sign in / Sign up

Export Citation Format

Share Document